CancerIQ, a Chicago, IL-based cancer detection and prevention company, raised $14M in Series B funding.
The round was led by Merck Global Health Innovation Fund and Amgen Ventures with participation from McKesson Ventures, OSF Ventures, and HealthX Ventures.
The company intends to use the funds to grow its precision health platform, strengthen its partnership ecosystem, and expand its health system network.
Led by CEO Feyi Olopade Ayodele, and Chief Scientific Advisor Olufunmilayo (Funmi) Olopade, MD, CancerIQ provides a precision health platform that makes it easy to determine a patient’s individual risk of cancer based on family history, genetics, behavior, and other factors, and then connect them to the corresponding care pathways. Those pathways range from MRIs, prophylactic surgeries and vaccinations to at-home screening kits, multi-cancer early detection (MCED) tests, lifestyle interventions and other services such as clinical trials, educational materials, and social resources. CancerIQ is embedded directly into EMR workflows so clinicians in any care setting have the latest genomics research, clinical guidelines, and life sciences innovations at their fingertips.
The precision health platform is being used by clinicians at more than 180 locations across the country,
FinSMEs
04/03/2022